Clinical Trial Update: A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PF-04236921 for efficacy and safety in Crohn's disease patients who failed anti-TNF therapy has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• PF-04236921

Snippet

Sponsor: Pfizer | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-01-21